Bain Capital Life Sciences Fund II, L.P. - 31 Dec 2025 SCHEDULE 13G/A Report for Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share (XLO)

Filing Manager
Bain Capital Life Sciences Fund II, L.P.
Reporting Manager
BCLS II Equity Opportunities, LP
Security
Xilio Therapeutics, Inc. Common Stock, par value $0.0001 per share
Symbol
XLO
Shares outstanding
73,644,024 shares
Disclosed Ownership
6,259,742 shares
Ownership
8.5%
Form type
SCHEDULE 13G/A
Filing time
17 Feb 2026, 16:30:03 UTC
Date of event
31 Dec 2025
SEC
View on sec.gov

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Bain Capital Life Sciences Fund II, L.P. 1.3% 992,111 0 992,111 /s/ Andrew Hack Andrew Hack, Partner of Bain Capital Life Sciences Investors, LLC
BCIP Life Sciences Associates, LP 0.2% 120,833 0 120,833 /s/ Andrew Hack Andrew Hack, Authorized Signatory of Boylston Coinvestors, LLC
BCLS II Equity Opportunities, LP 8.5% 6,259,742 0 6,259,742 /s/ Andrew Hack Andrew Hack, Partner of Bain Capital Life Sciences Investors, LLC
BCLS II Investco, LP 0% 0 0 0 /s/ Andrew Hack Andrew Hack, Partner of Bain Capital Life Sciences Investors, LLC